
Qifeng Yang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/839700/publications.pdf Version: 2024-02-01



OIFENC YANG

#	Article	IF	CITATIONS
1	Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer. Journal of Clinical Oncology, 2006, 24, 5652-5657.	1.6	956
2	Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets. Seminars in Cancer Biology, 2020, 60, 14-27.	9.6	460
3	Differential effects on lung and bone metastasis of breast cancer by Wnt signalling inhibitor DKK1. Nature Cell Biology, 2017, 19, 1274-1285.	10.3	218
4	SREBP1, targeted by miR-18a-5p, modulates epithelial-mesenchymal transition in breast cancer via forming a co-repressor complex with Snail and HDAC1/2. Cell Death and Differentiation, 2019, 26, 843-859.	11.2	130
5	Epigenetic Regulation of <i>NAMPT</i> by <i>NAMPT-AS</i> Drives Metastatic Progression in Triple-Negative Breast Cancer. Cancer Research, 2019, 79, 3347-3359.	0.9	103
6	miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma. Oncotarget, 2014, 5, 10816-10829.	1.8	91
7	Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas. Cancer, 2001, 92, 54-60.	4.1	81
8	Epigenetic Activation of TWIST1 by MTDH Promotes Cancer Stem–like Cell Traits in Breast Cancer. Cancer Research, 2015, 75, 3672-3680.	0.9	76
9	miR-409-3p suppresses breast cancer cell growth and invasion by targeting Akt1. Biochemical and Biophysical Research Communications, 2016, 469, 189-195.	2.1	64
10	Cepharanthine Induces Autophagy, Apoptosis and Cell Cycle Arrest in Breast Cancer Cells. Cellular Physiology and Biochemistry, 2017, 41, 1633-1648.	1.6	63
11	Long noncoding RNA LINP1 acts as an oncogene and promotes chemoresistance in breast cancer. Cancer Biology and Therapy, 2018, 19, 120-131.	3.4	62
12	Borderline ER-Positive Primary Breast Cancer Gains No Significant Survival Benefit From Endocrine Therapy: A Systematic Review and Meta-Analysis. Clinical Breast Cancer, 2018, 18, 1-8.	2.4	61
13	CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer. PLoS Biology, 2018, 16, e2005869.	5.6	60
14	MicroRNA-339-5p inhibits colorectal tumorigenesis through regulation of the MDM2/p53 signaling. Oncotarget, 2014, 5, 9106-9117.	1.8	58
15	Retinoid, Retinoic Acid Receptor \hat{I}^2 and Breast Cancer. Breast Cancer Research and Treatment, 2002, 76, 167-173.	2.5	51
16	Identification of Prognostic Alternative Splicing Signature in Breast Carcinoma. Frontiers in Genetics, 2019, 10, 278.	2.3	49
17	Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer. Clinical Cancer Research, 2002, 8, 2890-3.	7.0	49
18	Trail Resistance Induces Epithelial-Mesenchymal Transition and Enhances Invasiveness by Suppressing PTEN via miR-221 in Breast Cancer. PLoS ONE, 2014, 9, e99067.	2.5	45

QIFENG YANG

#	Article	IF	CITATIONS
19	Huaier Extract Inhibits Breast Cancer Progression Through a LncRNA-H19/MiR-675-5p Pathway. Cellular Physiology and Biochemistry, 2017, 44, 581-593.	1.6	45
20	The CUL4B/AKT/β-Catenin Axis Restricts the Accumulation of Myeloid-Derived Suppressor Cells to Prohibit the Establishment of a Tumor-Permissive Microenvironment. Cancer Research, 2015, 75, 5070-5083.	0.9	42
21	EGFL9 promotes breast cancer metastasis by inducing cMET activation and metabolic reprogramming. Nature Communications, 2019, 10, 5033.	12.8	42
22	Comparative prognostic analysis for triple-negative breast cancer with metaplastic and invasive ductal carcinoma. Journal of Clinical Pathology, 2019, 72, 418-424.	2.0	37
23	LncRNA LINP1 confers tamoxifen resistance and negatively regulated by ER signaling in breast cancer. Cellular Signalling, 2020, 68, 109536.	3.6	35
24	Bioinformatics-based interaction analysis of miR-92a-3p and key genes in tamoxifen-resistant breast cancer cells. Biomedicine and Pharmacotherapy, 2018, 107, 117-128.	5.6	33
25	Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy. Oncology Reports, 2003, 10, 121-5.	2.6	31
26	The prognosis of invasive micropapillary carcinoma compared with invasive ductal carcinoma in the breast: a meta-analysis. BMC Cancer, 2017, 17, 839.	2.6	30
27	Disulfiram and BKM120 in Combination with Chemotherapy Impede Tumor Progression and Delay Tumor Recurrence in Tumor Initiating Cell-Rich TNBC. Scientific Reports, 2019, 9, 236.	3.3	29
28	53 BP 1 suppresses epithelial–mesenchymal transition by downregulating ZEB 1 through micro RNA â€⊋00b/429 in breast cancer. Cancer Science, 2015, 106, 982-989.	3.9	28
29	Dose invasive apocrine adenocarcinoma has worse prognosis than invasive ductal carcinoma of breast: evidence from SEER database. Oncotarget, 2017, 8, 24579-24592.	1.8	28
30	Huaier aqueous extract inhibits cervical cancer cell proliferation via JNK/p38 pathway. International Journal of Oncology, 2015, 47, 1054-1060.	3.3	27
31	<i>JAM3</i> methylation status as a biomarker for diagnosis of preneoplastic and neoplastic lesions of the cervix. Oncotarget, 2015, 6, 44373-44387.	1.8	27
32	A novel long non-coding RNA AC073352.1 promotes metastasis and angiogenesis via interacting with YBX1 in breast cancer. Cell Death and Disease, 2021, 12, 670.	6.3	26
33	Radiosensitization effect of Huaier on breast cancer cells. Oncology Reports, 2016, 35, 2843-2850.	2.6	22
34	The oncogenic potentials and diagnostic significance of long nonâ€coding RNA LINC00310 in breast cancer. Journal of Cellular and Molecular Medicine, 2018, 22, 4486-4495.	3.6	21
35	Huaier extract restrains the proliferative potential of endocrine-resistant breast cancer cells through increased ATM by suppressing miR-203. Scientific Reports, 2017, 7, 7313.	3.3	20
36	Huaier aqueous extract protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting NLRP3 inflammasome activation. Oncotarget, 2017, 8, 32937-32945.	1.8	19

QIFENG YANG

#	Article	IF	CITATIONS
37	Knockdown of metadherin inhibits angiogenesis in breast cancer. International Journal of Oncology, 2015, 46, 2459-2466.	3.3	17
38	Identification of multi-target effects of Huaier aqueous extract via microarray profiling in triple-negative breast cancer cells. International Journal of Oncology, 2015, 46, 2047-2056.	3.3	16
39	MTDH Promotes Intestinal Inflammation by Positively Regulating TLR Signalling. Journal of Crohn's and Colitis, 2021, 15, 2103-2117.	1.3	15
40	Clinicopathological features of granulomatous lobular mastitis and mammary duct ectasia. Oncology Letters, 2020, 19, 840-848.	1.8	14
41	BRCA1 in non-inherited breast carcinomas (Review). Oncology Reports, 2002, 9, 1329-33.	2.6	14
42	Impact of histotypes on preferential organâ€specific metastasis in tripleâ€negative breast cancer. Cancer Medicine, 2020, 9, 872-881.	2.8	13
43	Relationship between Upper Extremity Lymphatic Drainage and Sentinel Lymph Nodes in Patients with Breast Cancer. Journal of Oncology, 2019, 2019, 1-7.	1.3	12
44	Identification of DGUOK-AS1 as a Prognostic Factor in Breast Cancer by Bioinformatics Analysis. Frontiers in Oncology, 2020, 10, 1092.	2.8	12
45	Special subtypes with favorable prognosis in breast cancer: A registry-based cohort study and network meta-analysis. Cancer Treatment Reviews, 2020, 91, 102108.	7.7	11
46	A genetic variant in p63 (rs17506395) is associated with breast cancer susceptibility and prognosis. Gene, 2014, 535, 170-176.	2.2	10
47	Periareolar incision for the management of benign breast tumors. Oncology Letters, 2016, 12, 3259-3263.	1.8	9
48	Precise intraoperative sentinel lymph node biopsies guided by lymphatic drainage in breast cancer. Oncotarget, 2017, 8, 63064-63072.	1.8	9
49	Enhanced effect of photodynamic therapy in ovarian cancer using a nanoparticle drug delivery system. International Journal of Oncology, 2015, 47, 1070-1076.	3.3	8
50	Internal Mammary Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer. Journal of Breast Cancer, 2018, 21, 442.	1.9	8
51	Exosomal non-coding RNAs: Emerging roles in bilateral communication between cancer cells and macrophages. Molecular Therapy, 2022, 30, 1036-1053.	8.2	8
52	Development and validation of a surgical-pathologic staging and scoring system for cervical cancer. Oncotarget, 2016, 7, 21054-21063.	1.8	7
53	53BP1 inhibits the migration and regulates the chemotherapy resistance of ovarian cancer cells. Oncology Letters, 2018, 15, 9917-9922.	1.8	7
54	Individualized Prediction of Survival Benefit from Postmastectomy Radiotherapy for Patients with Breast Cancer with One to Three Positive Axillary Lymph Nodes. Oncologist, 2019, 24, e1286-e1293.	3.7	7

QIFENG YANG

#	Article	IF	CITATIONS
55	Identification and preservation of stained non‑sentinel lymph nodes in breast cancer. Oncology Letters, 2020, 20, 1-1.	1.8	7
56	Evaluation of Carbon Nanoparticle Suspension and Methylene Blue Localization for Preoperative Localization of Nonpalpable Breast Lesions: A Comparative Study. Frontiers in Surgery, 2021, 8, 757694.	1.4	6
57	Cooperative oncogenic effect and cell signaling crosstalk of co-occurring HER2 and mutant PIK3CA in mammary epithelial cells. International Journal of Oncology, 2017, 51, 1320-1330.	3.3	5
58	The Fragile Histidine Triad gene and breast cancer. Medical Science Monitor, 2002, 8, RA140-4.	1.1	5
59	rs621554 single nucleotide polymorphism of DLC1 is associated with breast cancer susceptibility and prognosis. Molecular Medicine Reports, 2016, 13, 4095-4100.	2.4	3
60	Evaluation of efficacy of chemotherapy for mucinous carcinoma: a surveillance, epidemiology, and end results cohort study. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097560.	3.2	3
61	Comparison of adjuvant ED and EC-D regimens in operable breast invasive ductal carcinoma. Oncology Letters, 2016, 12, 1448-1454.	1.8	2
62	Galactogram Grading System for Identifying Breast Cancer With Nipple Discharge. Clinical Breast Cancer, 2020, 20, e214-e219.	2.4	1
63	A High Epigenetic Risk Score Shapes the Non-Inflamed Tumor Microenvironment in Breast Cancer. Frontiers in Molecular Biosciences, 2021, 8, 675198.	3.5	1
64	Loss of Msh2 is not associated with FHIT deletion in breast carcinomas. Anticancer Research, 2002, 22, 2591-5.	1.1	1
65	Enlarged paraâ€sentinel lymph node dissection is not necessary in breast cancer patients undergoing sentinel lymph node biopsy. Breast Journal, 2019, 25, 1025-1028.	1.0	0
66	A multiplex methylation-specific PCR assay for detection of early-stage ovarian cancer using cell-free serum DNA Journal of Clinical Oncology, 2013, 31, 5535-5535.	1.6	0